The Online Investor
Diagnostics M&A image Diagnostics M&A » By The Online Investor Staff, updated Sat., Feb. 29, 2:22 AM Recent mergers and acquisitions in the Diagnostics M&A category.

Slide #22. ExamWorks Group, Inc. Gould & Lamb

Acquirer: ExamWorks Group, Inc. (EXAM)
Acquiree: Gould & Lamb
Details: ExamWorks Group, Inc. (NYSE:EXAM), a leading provider of independent medical examinations (IMEs), peer reviews, bill reviews and related services, today announced the acquisition of Gould & Lamb, the leader in the Medicare compliance services market. The acquisition of Gould & Lamb establishes ExamWorks as the market leader in the Medicare compliance services market. This acquisition is consistent with ExamWorks' successful execution of its growth and expansion strategy in areas necessary for its customers to manage cost and compliance requirements. Medicare compliance and related services are offered to the same types of customers ExamWorks already services, and like IMEs, the Medicare compliance services industry is characterized by a large number of small providers without the scale and geographic scope to adequately serve the increasingly complicated and demanding needs of large national clients.

ExamWorks is a provider of independent medical examinations, peer reviews, bill reviews, Medicare compliance, case management, record retrieval, document management and other related services (IME services). Co. provides the majority of these IME services through its medical panel of physicians and other medical providers. Co.'s clients include property and casualty insurance carriers, law firms, third-party claim administrators, and government agencies that use independent services to confirm the veracity of claims by sick or injured individuals for workers' compensation, automotive, personal injury liability and disability insurance coverage.

Open the EXAM Page at The Online Investor »

Company Name: 
ExamWorks Group Inc

Open the EXAM Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Diagnostics M&A - Slide 22 of 100 Page |

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.